Schedule 13G filing

Decheng Capital Global Life Sciences Fund IV, L.P. cut its UPB stake below 5%

Schedule 13G · Filed Oct 29, 2026

Decheng Capital Global Life Sciences Fund IV, L.P. reported owning 4.9% of Upstream Bio, Inc. (UPB) (2,724,868 shares) in a Schedule 13G filed Oct 29, 2026.

A 13G is a passive stake: the holder does not plan to push for changes.

Exited

UPB

Upstream Bio, Inc.

Stake

4.9% stake

Disclosed: Oct 29, 2026
Source: Schedule 13G

See the filing

More UPB insider and Congress trades

SellUPB · Everett Rand Sutherland$12KSep 17, 2026
SellUPB · Aaron Deykin$5KSep 17, 2026
SellUPB · Michael Gray$5KSep 17, 2026
SellUPB · Adam Houghton$4KSep 17, 2026
SellUPB · Allison Ambrose$3KSep 17, 2026
SellUPB · Aaron Deykin$5KJun 17, 2026

Share this trade

From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.